AORT Stock Overview
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Artivion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.40 |
| 52 Week High | US$25.51 |
| 52 Week Low | US$12.16 |
| Beta | 1.67 |
| 1 Month Change | 8.13% |
| 3 Month Change | 36.36% |
| 1 Year Change | 58.75% |
| 3 Year Change | -18.81% |
| 5 Year Change | -22.08% |
| Change since IPO | 485.00% |
Recent News & Updates
Recent updates
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 08
Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion Stock: A First Assessment
Dec 27Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump
Nov 23Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
Oct 13Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
Jul 20Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M
Aug 04Is Artivion (NYSE:AORT) Using Too Much Debt?
Jun 27Is Artivion (NYSE:AORT) Using Too Much Debt?
Mar 25CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet
Dec 08CryoLife, Inc. (NYSE:CRY) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 01Shareholder Returns
| AORT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 13.9% | 1.2% | 2.7% |
| 1Y | 58.8% | -0.05% | 26.0% |
Return vs Industry: AORT exceeded the US Medical Equipment industry which returned -1.9% over the past year.
Return vs Market: AORT exceeded the US Market which returned 25% over the past year.
Price Volatility
| AORT volatility | |
|---|---|
| AORT Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AORT's share price has been volatile over the past 3 months.
Volatility Over Time: AORT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,500 | Pat Mackin | artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
Artivion, Inc. Fundamentals Summary
| AORT fundamental statistics | |
|---|---|
| Market cap | US$972.41m |
| Earnings (TTM) | -US$9.58m |
| Revenue (TTM) | US$368.21m |
2.7x
P/S Ratio-101.9x
P/E RatioIs AORT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AORT income statement (TTM) | |
|---|---|
| Revenue | US$368.21m |
| Cost of Revenue | US$129.81m |
| Gross Profit | US$238.40m |
| Other Expenses | US$247.98m |
| Earnings | -US$9.58m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 64.74% |
| Net Profit Margin | -2.60% |
| Debt/Equity Ratio | 106.2% |
How did AORT perform over the long term?
See historical performance and comparison